LA JOLLA, CALIF (October 12,
2022)– Calidi
Biotherapeutics, Inc. (Calidi), a clinical-stage
biotechnology company that is pioneering allogeneic cell-based platforms to
revolutionize oncolytic virus therapies, today announced a poster
presentation highlighting pre-clinical data from the company’s
SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of
Cancer (SITC) Annual Meeting, taking place in Boston, Massachusetts and
virtually, November 8-12, 2022.
Details of the poster presentation are below:
Title: SuperNova1 (SNV1), a novel
oncolytic-cell based platform for cancer therapy
Abstract ID: 1137
Location: Poster Hall C
Date: November 10, 2022, 9:00 a.m. –
9:00 p.m. ET
Presenters: Duong H. Nguyen, Ph.D., Director
of Translational Research and Innovation, and Antonio F. Santidrian, Ph.D.,
Senior Vice President, Global Head of Research and Development
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company
with proprietary technology that is revolutionizing the effective delivery
and potentiation of oncolytic viruses for targeted therapy against
difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent
allogeneic stem cell and oncolytic virus combination for use in multiple
oncology indications. Calidi’s off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses currently in development leading to enhanced efficacy and
improved patient safety. Calidi Biotherapeutics is headquartered in La
Jolla, California. For more information, please visit www.calidibio.com.
Contacts:
For Investors:
Stephen Jasper
stephen@gilmartinir.com
Forward-Looking Statements
This press release may contain forward-looking statements and
information relating to, among other things, Calidi Biotherapeutics and
its business plan and strategy, and the highly competitive
pharmaceutical industry. These forward-looking statements are based on
the beliefs of, assumptions made by, and information currently available
to the Company. When used in this press release, the words
“estimate,” “project,” “believe,”
“anticipate,” “intend,” “expect” as
well as similar terms, are forward-looking in nature. These
forward-looking statements involve a number of risks, uncertainties
(many of which are beyond Calidi’s control) or other assumptions
that may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking statements.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date on which
they are made. Calidi Biotherapeutics does not undertake any obligation
to revise or update these forward-looking statements to reflect events
or circumstances after such date or to reflect the occurrence of
unanticipated events.